SG10202010383YA - Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides - Google Patents

Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides

Info

Publication number
SG10202010383YA
SG10202010383YA SG10202010383YA SG10202010383YA SG10202010383YA SG 10202010383Y A SG10202010383Y A SG 10202010383YA SG 10202010383Y A SG10202010383Y A SG 10202010383YA SG 10202010383Y A SG10202010383Y A SG 10202010383YA SG 10202010383Y A SG10202010383Y A SG 10202010383YA
Authority
SG
Singapore
Prior art keywords
polypeptides
attaching
increasing
carboxy terminal
terminal peptides
Prior art date
Application number
SG10202010383YA
Inventor
Oren Hershkovitz
Ahuva Bar-Ilan
Original Assignee
Opko Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Biologics Ltd filed Critical Opko Biologics Ltd
Publication of SG10202010383YA publication Critical patent/SG10202010383YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
SG10202010383YA 2012-11-20 2013-11-20 Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides SG10202010383YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261728662P 2012-11-20 2012-11-20

Publications (1)

Publication Number Publication Date
SG10202010383YA true SG10202010383YA (en) 2020-11-27

Family

ID=50776635

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10202010383YA SG10202010383YA (en) 2012-11-20 2013-11-20 Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
SG10201610223PA SG10201610223PA (en) 2012-11-20 2013-11-20 Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
SG11201503879QA SG11201503879QA (en) 2012-11-20 2013-11-20 Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201610223PA SG10201610223PA (en) 2012-11-20 2013-11-20 Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
SG11201503879QA SG11201503879QA (en) 2012-11-20 2013-11-20 Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides

Country Status (20)

Country Link
US (1) US9808534B2 (en)
EP (2) EP2922867B1 (en)
JP (2) JP6416106B2 (en)
KR (2) KR102202255B1 (en)
CN (3) CN105121459A (en)
AU (1) AU2013349239B2 (en)
BR (2) BR112015011583B1 (en)
CA (1) CA2891393A1 (en)
CL (1) CL2015001347A1 (en)
EA (1) EA033788B1 (en)
ES (1) ES2882890T3 (en)
HU (1) HUE055348T2 (en)
IL (1) IL264700B (en)
MX (1) MX363326B (en)
MY (1) MY172997A (en)
PE (2) PE20151087A1 (en)
PL (1) PL2922867T3 (en)
PT (1) PT2922867T (en)
SG (3) SG10202010383YA (en)
WO (1) WO2014080401A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
JP6242819B2 (en) * 2012-02-14 2017-12-06 オプコ バイオロジクス リミテッド Long-acting coagulation factor and method for producing the same
EA201491898A1 (en) * 2012-04-19 2015-08-31 Опко Байолоджикс Лтд. OPTIONS OF OXINTOMODULIN PROLONGED ACTION AND METHODS OF OBTAINING THE SPECIFIED OPTIONS
EA033788B1 (en) 2012-11-20 2019-11-26 Opko Biologics Ltd Method of increasing the hydrodynamic volume of polypeptide by attaching to gonadotrophin carboxy terminal peptide
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
CN105461810A (en) * 2014-08-31 2016-04-06 复旦大学 Long-acting recombinant human granulocyte colony-stimulating factor and preparation method therefor and use thereof
MY184625A (en) 2014-12-10 2021-04-09 Opko Biologics Ltd Methods of producing long acting ctp-modified growth hormone polypeptides
AU2015358890B2 (en) * 2014-12-10 2019-06-13 Opko Biologics Ltd. Methods of producing long acting CTP-modified growth hormone polypeptides
AU2016280867B2 (en) 2015-06-19 2020-02-27 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
CN106397570B (en) * 2015-07-31 2019-11-15 袁武梅 A kind of carboxy terminal peptide and long-acting interferon
CN106397571A (en) * 2015-07-31 2017-02-15 李金松 Novel carboxyl-terminated peptide and long-acting interleukin 7
CN107759697B (en) * 2016-08-19 2023-03-24 安源医药科技（上海）有限公司 Method for producing fusion protein
CN106279437B (en) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 Hyperglycosylated human coagulation factor VIII fusion proteins and preparation method thereof and purposes
WO2021078834A1 (en) * 2019-10-22 2021-04-29 Genethon Chimeric acid-alpha glucosidase polypeptides and uses thereof

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (en) 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
NL154599B (en) 1970-12-28 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (en) 1972-05-11 1983-06-01 Akzo Nv METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
JPS5781447A (en) 1980-11-11 1982-05-21 Toyo Jozo Co Ltd Human chorionic gonadotropic hormone c-terminal fragment
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
DE3421468A1 (en) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim LIPID NANOPELLETS AS A CARRIER SYSTEM FOR MEDICINAL PRODUCTS FOR PERORAL USE
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4911691A (en) 1984-09-21 1990-03-27 Menlo Care, Inc. Assembly for adminstering IV solution
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
DE122007000007I1 (en) 1986-04-09 2007-05-16 Genzyme Corp Genetically transformed animals secreting a desired protein in milk
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
DE68917883T2 (en) 1988-05-06 1995-02-23 Toray Industries STABLE INTERFERON BETA COMPOSITION.
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5338835A (en) 1989-02-21 1994-08-16 Washington University CTP-extended form of FSH
US5705478A (en) 1989-02-21 1998-01-06 Washington University Covalently linked β subunits of the glycoprotein hormones as antagonists
US5792460A (en) 1989-02-21 1998-08-11 Washington University Modified glycoprotein hormones having a CTP at the amino terminus
DE69029799T2 (en) 1989-02-21 1997-05-28 Univ Washington MODIFIED FORMS OF REPRODUCTION HORMONES
US6225449B1 (en) 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US7217689B1 (en) 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US6028177A (en) 1991-10-04 2000-02-22 Washington University Methods of detecting single-chain forms of the glycoprotein hormone quartet
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
PT695307E (en) 1993-04-20 2000-05-31 Univ Washington PROTEINS AND MODIFIED PEPTID DRUGS
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US6737515B2 (en) 1993-11-19 2004-05-18 Washington University Follicle stimulating hormone-glycosylation analogs
US6238890B1 (en) 1994-02-18 2001-05-29 Washington University Single chain forms of the glycoprotein hormone quartet
US5935924A (en) 1994-04-15 1999-08-10 Genentech, Inc. Treatment of congestive heart failure
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
MX9601320A (en) 1994-08-12 1997-05-31 Univ Washington Single-chain forms of the glycoprotein hormone quartet.
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
TW518235B (en) 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
US6310183B1 (en) 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
US6103501A (en) 1997-11-17 2000-08-15 Washington University Single chain glycoprotein hormones comprising two β and one α subunits and recombinant production thereof
TR200101087T2 (en) 1998-10-16 2001-09-21 Biogen, Inc. Interferon beta-fusion proteins and their use
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythopintin derivatives
AU2001233299A1 (en) * 2000-02-04 2001-08-14 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US20020127652A1 (en) 2000-02-11 2002-09-12 Schambye Hans Thalsgard Follicle stimulating hormones
US7094566B2 (en) 2000-03-16 2006-08-22 Amgen Inc., IL-17 receptor like molecules and uses thereof
US20030036181A1 (en) 2000-06-30 2003-02-20 Okkels Jens Sigurd Peptide extended glycosylated polypeptides
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
ES2382636T3 (en) 2000-10-31 2012-06-12 Surmodics Pharmaceuticals, Inc. Method for producing compositions for improved administration of bioactive molecules
WO2002038609A2 (en) 2000-11-10 2002-05-16 Proteopharma Aps Apolipoprotein conjugates
DE60136958D1 (en) 2000-12-01 2009-01-22 Takeda Pharmaceutical METHOD FOR PRODUCING A PREPARATION WITH A BIOACTIVE SUBSTANCE
JP4409135B2 (en) 2000-12-01 2010-02-03 武田薬品工業株式会社 Manufacturing method of bioactive substance-containing preparation
PL209550B1 (en) 2000-12-07 2011-09-30 Lilly Co Eli Glp-1 fusion proteins
JP3946638B2 (en) 2000-12-11 2007-07-18 シージェイ コーポレーション Fusion protein with enhanced erythropoietin activity in vivo
KR101229995B1 (en) 2000-12-11 2013-02-06 씨제이 주식회사 Fusion protein having the enhanced in vivo activity of erythropoietin
US8637077B2 (en) 2000-12-28 2014-01-28 Takeda Pharmaceutical Company Limited Sustained-release preparation
JP5160005B2 (en) 2000-12-28 2013-03-13 武田薬品工業株式会社 Sustained release formulation
US6987172B2 (en) * 2001-03-05 2006-01-17 Washington University In St. Louis Multifunctional single chain glycoprotein hormones comprising three or more β subunits
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
EP1390053A2 (en) 2001-04-25 2004-02-25 Hernan F. Acevedo Hcg formulation
US6824769B2 (en) 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
JP4583029B2 (en) 2001-10-29 2010-11-17 クルセル ホランド ベー ヴェー Method and method for producing a protein having a predetermined post-translational modification
KR100467751B1 (en) 2001-12-03 2005-01-24 씨제이 주식회사 Fusion protein having the enhanced in vivo erythropoietin activity
ES2425738T3 (en) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Albumin Fusion Proteins
US7173113B2 (en) 2002-01-31 2007-02-06 The Trustees Of Columbia University In The City Of New York Long-acting hormone and growth factor compositions and uses thereof
US7081446B2 (en) 2002-01-31 2006-07-25 The Trustees Of Columbia University In The City Of New York Long-acting follicle stimulating hormone analogues and uses thereof
GB0206048D0 (en) 2002-03-14 2002-04-24 Croda Int Plc Use
GB2403476A (en) * 2002-05-13 2005-01-05 Modigenetech Ltd CTP-extended erythropoietin
US20070298041A1 (en) 2002-06-28 2007-12-27 Tomlinson Ian M Ligands That Enhance Endogenous Compounds
MXPA05000658A (en) 2002-07-17 2005-08-19 Biogen Idec Inc THERAPIES FOR RENAL FAILURE USING INTERFERON-beta.
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
WO2004073749A1 (en) 2003-02-19 2004-09-02 Takeda Pharmaceutical Company Limited Dispersant for sustained release preparations
JP4683319B2 (en) 2003-02-19 2011-05-18 武田薬品工業株式会社 Dispersant for sustained release preparation
PT1620118E (en) 2003-04-08 2014-10-16 Yeda Res & Dev Reversible pegylated drugs
SG155777A1 (en) 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
WO2005035761A1 (en) 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
US7649084B2 (en) 2003-11-12 2010-01-19 University Of Georgia Research Foundation, Inc. Recombinant glycoproteins related to feline thyrotropin
DK1696947T3 (en) 2003-12-19 2014-03-17 Hoffmann La Roche APPLICATION OF ERYTHROPOIETIN IN THE TREATMENT OF DISORDERS OF THE IRON DISTRIBUTION IN CHRONIC INFLAMMATORY INTESTINAL DISEASES
WO2005094873A1 (en) 2004-03-19 2005-10-13 Baxter International Inc. Factor ixa for the treatment of bleeding disorders
US20080206270A1 (en) 2004-07-08 2008-08-28 Minev Boris R Enhancing Class I Antigen Presentation With Synthetic Sequences
WO2006018204A1 (en) 2004-08-17 2006-02-23 Zlb Behring Gmbh Modified vitamin k dependent polypeptides
EP1802645A4 (en) 2004-09-27 2009-01-14 Cornell Res Foundation Inc Recombinant bifunctional protein of human lutropin receptor and human chorionic gonadotropin b-subunit and uses thereof
CN101724071A (en) 2004-10-08 2010-06-09 杜门蒂斯有限公司 Single domain antibodies against TNFRl and methods of use therefor
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
ATE553124T1 (en) 2005-06-13 2012-04-15 Imp Innovations Ltd OXYNTOMODULIN ANALOGS AND THEIR EFFECTS ON EATING BEHAVIOR
US8759290B2 (en) 2005-10-18 2014-06-24 Biocon Limited Oral glucagon-like peptide conjugates for metabolic diseases
US7553941B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8450269B2 (en) * 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US8304386B2 (en) * 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US7928058B2 (en) 2006-02-22 2011-04-19 Merck Sharp & Dohme Corp. Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
EP2423306A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
AT505262A1 (en) 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und New recombinant angiotensin I converting enzyme 2 polypeptide comprising specific amount of glycosylated and sugar portion, useful for enzyme substitution therapy for treating acute respiratory distress syndrome or acute lung injury
EP2225372A2 (en) 2007-12-05 2010-09-08 Novozymes A/S Polypeptides having endoglucanase activity and polynucleotides encoding same
MX2011000847A (en) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Conjugated proteins with prolonged in vivo efficacy.
EP2898900B1 (en) 2008-09-19 2017-11-15 Nektar Therapeutics Polymer conjugates of ziconotide
CN102413990A (en) 2009-02-27 2012-04-11 钴领无限公司 Modular automated tool dispenser
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
DE102009031992A1 (en) 2009-07-06 2011-01-13 Paul Hartmann Ag Device for negative pressure therapy of wounds
AR079345A1 (en) 2009-12-22 2012-01-18 Lilly Co Eli OXINTOMODULINE PEPTIDAL ANALOG
KR101382593B1 (en) 2010-07-21 2014-04-10 한미사이언스 주식회사 Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity
CN104023739A (en) 2011-06-02 2014-09-03 Opko生物科学有限公司 Long-acting glp-1/glucagon receptor agonists
EA201491898A1 (en) * 2012-04-19 2015-08-31 Опко Байолоджикс Лтд. OPTIONS OF OXINTOMODULIN PROLONGED ACTION AND METHODS OF OBTAINING THE SPECIFIED OPTIONS
CN109096387B (en) 2012-06-04 2021-11-30 奥普科生物制品有限公司 Pegylated OXM variants
EA033788B1 (en) 2012-11-20 2019-11-26 Opko Biologics Ltd Method of increasing the hydrodynamic volume of polypeptide by attaching to gonadotrophin carboxy terminal peptide
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same

Also Published As

Publication number Publication date
SG11201503879QA (en) 2015-06-29
EP2922867A4 (en) 2016-08-03
WO2014080401A3 (en) 2014-09-25
JP2016501198A (en) 2016-01-18
KR102202255B1 (en) 2021-01-13
PL2922867T3 (en) 2021-12-06
JP2019038812A (en) 2019-03-14
CN114317505A (en) 2022-04-12
SG10201610223PA (en) 2017-02-27
AU2013349239A1 (en) 2015-07-09
PE20210171A1 (en) 2021-01-29
EP2922867B1 (en) 2021-07-21
PT2922867T (en) 2021-10-29
CL2015001347A1 (en) 2015-09-04
AU2013349239B2 (en) 2018-04-12
EP3848386A1 (en) 2021-07-14
KR20150110486A (en) 2015-10-02
MY172997A (en) 2019-12-18
MX363326B (en) 2019-03-20
BR122020018510B1 (en) 2023-03-14
EA033788B1 (en) 2019-11-26
CN112661863A (en) 2021-04-16
MX2015006302A (en) 2016-03-11
KR20210016042A (en) 2021-02-10
JP6416106B2 (en) 2018-10-31
EP2922867A2 (en) 2015-09-30
KR102341581B1 (en) 2021-12-21
CN105121459A (en) 2015-12-02
CA2891393A1 (en) 2014-05-30
BR112015011583B1 (en) 2023-03-14
IL264700B (en) 2022-03-01
EA201590994A1 (en) 2016-03-31
ES2882890T3 (en) 2021-12-03
BR112015011583A2 (en) 2017-08-15
PE20151087A1 (en) 2015-08-28
US20140316112A1 (en) 2014-10-23
WO2014080401A2 (en) 2014-05-30
US9808534B2 (en) 2017-11-07
HUE055348T2 (en) 2021-11-29

Similar Documents

Publication Publication Date Title
IL264700B (en) Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
IL285015A (en) Recombinant cell surface capture proteins
HK1217731A1 (en) Heterodimerized polypeptide
HK1204799A1 (en) Waterproofing membrane
HK1206748A1 (en) Modified polynucleotides for the production of membrane proteins
EP2797634A4 (en) Modified mrnas encoding cell-penetrating polypeptides
EP2728002A4 (en) Heterodimerized polypeptide
HK1213521A1 (en) Methods of using fix polypeptides fix
GB201012988D0 (en) Dehydration of liquid fuel
HK1204488A1 (en) Electrochemical compression system
HK1208810A1 (en) C-terminal and central epitope a-beta antibodies c a-
GB201222833D0 (en) Detection of membrane proteins
HK1208040A1 (en) Cell penetrating peptides to target eif4e eif4e
HK1198926A1 (en) Tyrosine based linkers for the releasable connection of peptides
SG10201501080VA (en) Method For The Determination Of Sequence Variants Of Polypeptides
GB201220021D0 (en) Fuel cell components
SG11201504860PA (en) Porous metallic membrane
GB201313231D0 (en) Fuel Cell Components
HUP1200171A1 (en) Methods for the production of polypeptides
GB201220036D0 (en) Fuel cell components
IL238904A0 (en) Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
EP2849793A4 (en) Affinity peptides toward infliximab
GB201215288D0 (en) Improvements relating to firelighters